GSK (GSK) Competitors

$51.70 +0.21 (+0.40%)

As of 01:54 PM Eastern

GSK vs. AZN, NVS, NVO, SNY, and TAK

Should you buy GSK stock or one of its competitors? MarketBeat compares GSK with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with GSK include Astrazeneca (AZN), Novartis (NVS), Novo Nordisk A/S (NVO), Sanofi (SNY), and Takeda Pharmaceutical (TAK). These companies are all part of the "pharmaceutical products" industry.

How does GSK compare to Astrazeneca?

Astrazeneca (NYSE:AZN) and GSK (NYSE:GSK) are both large-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

Astrazeneca has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market. Comparatively, GSK has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market.

20.4% of Astrazeneca shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 10.0% of GSK shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

GSK has a net margin of 17.82% compared to Astrazeneca's net margin of 17.19%. GSK's return on equity of 44.28% beat Astrazeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrazeneca	17.19%	30.86%	12.68%
GSK	17.82%	44.28%	11.49%

Astrazeneca has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrazeneca	$58.74B	4.94	$10.23B	$6.66	28.08
GSK	$32.78B	3.20	$7.54B	$3.85	13.43

In the previous week, Astrazeneca had 6 more articles in the media than GSK. MarketBeat recorded 10 mentions for Astrazeneca and 4 mentions for GSK. Astrazeneca's average media sentiment score of 0.73 beat GSK's score of 0.59 indicating that Astrazeneca is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrazeneca	3 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Positive
GSK	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.3%. GSK pays an annual dividend of $1.81 per share and has a dividend yield of 3.5%. Astrazeneca pays out 65.2% of its earnings in the form of a dividend. GSK pays out 47.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.

Astrazeneca currently has a consensus target price of $205.33, indicating a potential upside of 9.79%. GSK has a consensus target price of $53.00, indicating a potential upside of 2.47%. Given Astrazeneca's stronger consensus rating and higher probable upside, equities analysts plainly believe Astrazeneca is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrazeneca	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
GSK	3 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.90

Summary

Astrazeneca beats GSK on 12 of the 18 factors compared between the two stocks.

How does GSK compare to Novartis?

GSK (NYSE:GSK) and Novartis (NYSE:NVS) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

GSK has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market. Comparatively, Novartis has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market.

GSK pays an annual dividend of $1.81 per share and has a dividend yield of 3.5%. Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.0%. GSK pays out 47.0% of its earnings in the form of a dividend. Novartis pays out 44.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

GSK presently has a consensus price target of $53.00, indicating a potential upside of 2.47%. Novartis has a consensus price target of $141.20, indicating a potential downside of 6.61%. Given GSK's higher probable upside, equities research analysts clearly believe GSK is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	3 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.90
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31

In the previous week, GSK had 1 more articles in the media than Novartis. MarketBeat recorded 4 mentions for GSK and 3 mentions for Novartis. GSK's average media sentiment score of 0.59 beat Novartis' score of 0.25 indicating that GSK is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novartis	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Novartis has higher revenue and earnings than GSK. GSK is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$32.78B	3.20	$7.54B	$3.85	13.43
Novartis	$56.58B	5.10	$13.98B	$6.98	21.66

Novartis has a net margin of 24.87% compared to GSK's net margin of 17.82%. GSK's return on equity of 44.28% beat Novartis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	17.82%	44.28%	11.49%
Novartis	24.87%	38.82%	15.16%

15.7% of GSK shares are held by institutional investors. Comparatively, 13.1% of Novartis shares are held by institutional investors. 10.0% of GSK shares are held by company insiders. Comparatively, 0.0% of Novartis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Novartis beats GSK on 11 of the 18 factors compared between the two stocks.

How does GSK compare to Novo Nordisk A/S?

GSK (NYSE:GSK) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.

GSK pays an annual dividend of $1.81 per share and has a dividend yield of 3.5%. Novo Nordisk A/S pays an annual dividend of $1.74 per share and has a dividend yield of 3.9%. GSK pays out 47.0% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 40.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

Novo Nordisk A/S has higher revenue and earnings than GSK. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$32.78B	3.20	$7.54B	$3.85	13.43
Novo Nordisk A/S	$327.80B	0.61	$15.51B	$4.26	10.52

Novo Nordisk A/S has a net margin of 37.23% compared to GSK's net margin of 17.82%. Novo Nordisk A/S's return on equity of 63.31% beat GSK's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	17.82%	44.28%	11.49%
Novo Nordisk A/S	37.23%	63.31%	22.19%

15.7% of GSK shares are held by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are held by institutional investors. 10.0% of GSK shares are held by company insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Novo Nordisk A/S had 46 more articles in the media than GSK. MarketBeat recorded 50 mentions for Novo Nordisk A/S and 4 mentions for GSK. Novo Nordisk A/S's average media sentiment score of 0.92 beat GSK's score of 0.59 indicating that Novo Nordisk A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novo Nordisk A/S	29 Very Positive mention(s)	6 Positive mention(s)	9 Neutral mention(s)	6 Negative mention(s)	0 Very Negative mention(s)	Positive

GSK has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market.

GSK currently has a consensus price target of $53.00, suggesting a potential upside of 2.47%. Novo Nordisk A/S has a consensus price target of $65.56, suggesting a potential upside of 46.23%. Given Novo Nordisk A/S's stronger consensus rating and higher probable upside, analysts clearly believe Novo Nordisk A/S is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	3 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.90
Novo Nordisk A/S	1 Sell rating(s)	18 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.13

Summary

Novo Nordisk A/S beats GSK on 14 of the 18 factors compared between the two stocks.

How does GSK compare to Sanofi?

Sanofi (NASDAQ:SNY) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk.

Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.0%. GSK pays an annual dividend of $1.81 per share and has a dividend yield of 3.5%. Sanofi pays out 49.2% of its earnings in the form of a dividend. GSK pays out 47.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Sanofi has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market. Comparatively, GSK has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market.

GSK has a net margin of 17.82% compared to Sanofi's net margin of 16.95%. GSK's return on equity of 44.28% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	16.95%	13.39%	7.58%
GSK	17.82%	44.28%	11.49%

Sanofi presently has a consensus target price of $51.00, indicating a potential upside of 14.53%. GSK has a consensus target price of $53.00, indicating a potential upside of 2.47%. Given Sanofi's stronger consensus rating and higher probable upside, research analysts plainly believe Sanofi is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47
GSK	3 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.90

In the previous week, GSK had 4 more articles in the media than Sanofi. MarketBeat recorded 4 mentions for GSK and 0 mentions for Sanofi. GSK's average media sentiment score of 0.59 beat Sanofi's score of -0.33 indicating that GSK is being referred to more favorably in the news media.

Company	Overall Sentiment
Sanofi	Neutral
GSK	Positive

Sanofi has higher revenue and earnings than GSK. Sanofi is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$47.35B	2.29	$8.84B	$3.58	12.44
GSK	$32.78B	3.20	$7.54B	$3.85	13.43

14.0% of Sanofi shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 1.0% of Sanofi shares are owned by insiders. Comparatively, 10.0% of GSK shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

GSK beats Sanofi on 12 of the 19 factors compared between the two stocks.

How does GSK compare to Takeda Pharmaceutical?

GSK (NYSE:GSK) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, media sentiment, dividends, profitability, valuation and risk.

15.7% of GSK shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 10.0% of GSK shares are owned by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

GSK has higher earnings, but lower revenue than Takeda Pharmaceutical. GSK is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$32.78B	3.20	$7.54B	$3.85	13.43
Takeda Pharmaceutical	$4.51T	0.01	$1.27B	$0.39	41.50

GSK has a net margin of 17.82% compared to Takeda Pharmaceutical's net margin of 4.31%. GSK's return on equity of 44.28% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	17.82%	44.28%	11.49%
Takeda Pharmaceutical	4.31%	11.07%	5.49%

In the previous week, GSK had 4 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 4 mentions for GSK and 0 mentions for Takeda Pharmaceutical. GSK's average media sentiment score of 0.59 beat Takeda Pharmaceutical's score of -0.82 indicating that GSK is being referred to more favorably in the media.

Company	Overall Sentiment
GSK	Positive
Takeda Pharmaceutical	Negative

GSK currently has a consensus target price of $53.00, indicating a potential upside of 2.47%. Given GSK's higher possible upside, equities analysts plainly believe GSK is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	3 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.90
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

GSK has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market.

GSK pays an annual dividend of $1.81 per share and has a dividend yield of 3.5%. Takeda Pharmaceutical pays an annual dividend of $0.50 per share and has a dividend yield of 3.1%. GSK pays out 47.0% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 128.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

GSK beats Takeda Pharmaceutical on 14 of the 17 factors compared between the two stocks.

Get GSK News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GSK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GSK vs. The Competition

Export

Metric	GSK	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$104.94B	$3.38B	$6.39B	$23.20B
Dividend Yield	3.53%	2.26%	2.76%	4.09%
P/E Ratio	13.44	19.00	20.84	31.02
Price / Sales	3.20	193.68	514.47	73.33
Price / Cash	8.56	125.17	43.49	25.06
Price / Book	4.47	7.18	10.44	4.80
Net Income	$7.54B	$24.25M	$3.57B	$1.07B
7 Day Performance	1.87%	4.76%	3.02%	2.07%
1 Month Performance	-4.64%	3.79%	2.47%	1.65%
1 Year Performance	31.14%	65.94%	36.43%	27.30%

GSK Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GSK GSK	3.1273 of 5 stars	$51.72 +0.4%	$53.00 +2.5%	+33.1%	$104.94B	$32.78B	13.44	66,841	Dividend Cut
AZN Astrazeneca	3.7945 of 5 stars	$187.24 +0.1%	$205.33 +9.7%	N/A	$290.39B	$58.74B	28.11	96,100
NVS Novartis	3.2034 of 5 stars	$152.14 +0.1%	$141.20 -7.2%	+33.6%	$290.31B	$54.53B	21.80	75,267
NVO Novo Nordisk A/S	4.7775 of 5 stars	$44.91 -0.1%	$65.56 +46.0%	-34.2%	$200.52B	$46.80B	10.54	69,505	Trending News
SNY Sanofi	3.7304 of 5 stars	$44.29 flat	$51.00 +15.2%	-15.1%	$108.02B	$49.35B	12.37	74,846

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:GSK) was last updated on 5/27/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GSK (GSK) Competitors